Test bed

The chart shows the growth of an initial investment of $10,000 in Test bed, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

As of Apr 3, 2026, the Test bed returned 1.65% Year-To-Date and 15.34% of annualized return in the last 10 years.

Based on dividend-adjusted daily data since Oct 21, 2011, Test bed's average daily return is +0.06%, while the average monthly return is +1.27%. At this rate, your investment would double in approximately 4.6 years.

Historically, 69% of months were positive and 31% were negative. The best month was Apr 2020 with a return of +13.6%, while the worst month was Mar 2020 at -10.9%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 3 months.

On a daily basis, Test bed closed higher 55% of trading days. The best single day was Apr 9, 2025 with a return of +9.3%, while the worst single day was Mar 16, 2020 at -11.4%.

Test bed has an annualized alpha of 2.89%, beta of 0.99, and R² of 0.98 versus S&P 500 Index. Calculated based on daily prices since October 21, 2011.

• This portfolio captured 108.11% of S&P 500 Index gains but only 94.09% of its losses — a favorable profile for investors.
• This portfolio generated an annualized alpha of 2.89% versus S&P 500 Index — delivering returns beyond what market exposure alone would predict.
• With beta of 0.99 and R² of 0.98, this portfolio moves broadly in line with S&P 500 Index — much of its variation is explained by market exposure rather than independent behavior.

Test bed has an expense ratio of 0.09%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

Test bed ranks 40 for risk / return — on par with similar portfolios. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Test bed Sharpe ratios as of Apr 3, 2026 (values are recalculated daily):

• 1-Year: 1.09
• 5-Year: 0.67
• 10-Year: 0.85
• All Time: 0.92

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 1.00 to 1.68, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of Test bed compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

Test bed provided a 1.70% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Test bed. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Test bed was 31.80%, occurring on Mar 23, 2020. Recovery took 82 trading sessions.

The current Test bed drawdown is 3.86%.

The chart below shows the rolling one-month volatility.